Mitoxantrone
Mitoxantrone (mitoxantrone) is a small molecule pharmaceutical. Mitoxantrone was first approved as Novantrone on 1987-12-23. It is used to treat breast neoplasms, lymphoma, multiple sclerosis, myeloid leukemia acute, and pain amongst others in the USA. It is known to target DNA topoisomerase 2-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Mitoxantrone (discontinued: Mitoxantrone, Novantrone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitoxantrone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NOVANTRONE | EMD Serono | N-019297 DISCN | 1987-12-23 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| mitoxantrone | ANDA | 2024-10-15 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg |
Clinical
Clinical Trials
397 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 72 | 88 | 47 | 10 | 9 | 197 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 54 | 59 | 36 | 4 | 10 | 144 |
| Myeloid leukemia | D007951 | — | C92 | 54 | 57 | 30 | 3 | 9 | 135 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 13 | 21 | 6 | 3 | 1 | 39 |
| Lymphoid leukemia | D007945 | — | C91 | 10 | 22 | 6 | 3 | 1 | 37 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 4 | 2 | 1 | 5 | 12 |
| Sclerosis | D012598 | — | — | — | 4 | 2 | 1 | 5 | 12 |
| Promyelocytic leukemia acute | D015473 | — | C92.4 | — | 1 | 4 | 3 | — | 8 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 3 | — | 1 | 2 | 6 |
| Philadelphia chromosome | D010677 | — | — | 1 | 1 | — | 1 | — | 3 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 19 | 55 | 18 | — | 9 | 90 |
| Myelodysplastic syndromes | D009190 | — | D46 | 12 | 14 | 9 | — | 1 | 32 |
| Prostatic neoplasms | D011471 | — | C61 | 7 | 21 | 8 | — | — | 32 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 15 | 8 | — | — | 26 |
| Preleukemia | D011289 | — | — | 10 | 10 | 9 | — | — | 25 |
| Syndrome | D013577 | — | — | 8 | 11 | 7 | — | — | 22 |
| Recurrence | D012008 | — | — | 9 | 8 | 2 | — | 2 | 19 |
| Neoplasms | D009369 | — | C80 | 12 | 8 | 1 | — | — | 19 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 4 | 12 | 1 | — | 3 | 17 |
| T-cell lymphoma peripheral | D016411 | — | — | 6 | 10 | 1 | — | 3 | 16 |
Show 24 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| T-cell lymphoma | D016399 | — | — | 6 | 9 | — | — | 4 | 15 |
| Myelomonocytic leukemia acute | D015479 | — | C92.5 | 9 | 5 | — | — | — | 13 |
| Erythroblastic leukemia acute | D004915 | EFO_1001257 | C94.0 | 8 | 5 | — | — | — | 12 |
| Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 8 | 4 | — | — | — | 11 |
| Mantle-cell lymphoma | D020522 | — | — | — | 6 | — | — | — | 6 |
| Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 2 | 3 | — | — | — | 4 |
| Biphenotypic leukemia acute | D015456 | — | C95.0 | 3 | 3 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 3 | — | — | — | 4 |
| Plasma cell neoplasms | D054219 | — | — | 3 | 3 | — | — | — | 4 |
| Sarcoma | D012509 | — | — | 2 | 2 | — | — | — | 4 |
Show 37 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | — | — | 4 | 4 |
| Classical conditioning | D003214 | — | — | — | — | — | — | 3 | 3 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | — | — | — | — | 1 | 1 |
| Drug therapy | D004358 | — | — | — | — | — | — | 1 | 1 |
| Malignant mesothelioma | D000086002 | — | — | — | — | — | — | 1 | 1 |
| Mesothelioma | D008654 | — | C45 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mitoxantrone |
| INN | mitoxantrone |
| Description | Mitoxantrone is a dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. It has a role as an antineoplastic agent and an analgesic. |
| Classification | Small molecule |
| Drug class | antineoplastics, anthraquinone derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21 |
Identifiers
| PDB | — |
| CAS-ID | 65271-80-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL58 |
| ChEBI ID | 50729 |
| PubChem CID | 4212 |
| DrugBank | DB01204 |
| UNII ID | BZ114NVM5P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TOP2A
TOP2A
Organism
Homo sapiens
Gene name
TOP2A
Gene synonyms
TOP2
NCBI Gene ID
Protein name
DNA topoisomerase 2-alpha
Protein synonyms
DNA gyrase, DNA topoisomerase (ATP-hydrolyzing), DNA topoisomerase II, 170 kD, DNA topoisomerase II, alpha isozyme, topoisomerase (DNA) II alpha 170kDa
Uniprot ID
Mouse ortholog
Top2a (21973)
DNA topoisomerase 2-alpha (Q01320)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,806 documents
View more details
Safety
Black-box Warning
Black-box warning for: Mitoxantrone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,548 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use